CLAIMS

1. A pharmaceutical composition, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and an auxiliary material; the auxiliary material comprises one or more of a filler, a binder, a glidant, a disintegrant and a lubricant; the filler is one or more of lactose, anhydrous lactose, microcrystalline cellulose, mannitol or starch; the binder is one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, Povidone, hydroxyethyl cellulose, sodium carboxymethyl cellulose or polyvinyl alcohol; the glidant is one or more of colloidal silica, talc or micronized silica gel; the disintegrant is one or more of low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch or cross-linked Povidone; the lubricant is one or more of magnesium stearate, calcium stearate or sodium stearyl fumarate; a mass ratio of the compound of Formula I to the filler is 1:1.0-2.5, a mass ratio of the compound of Formula I to the binder is 1:0.01-0.05, a mass ratio of the compound of Formula I to the glidant is 1:0.01-0.03, a mass ratio of the compound of Formula I to the disintegrant is 1:0.10-0.30, and a mass ratio of the compound of Formula I to the lubricant is 1:0.01-0.10;



I.

2. A pharmaceutical composition, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and an auxiliary material; the auxiliary material comprises one or more of a filler, a binder, a glidant, a disintegrant and a lubricant; the filler is one or more of lactose, anhydrous lactose, microcrystalline cellulose, mannitol or starch; the binder is one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, Povidone, hydroxyethyl cellulose, sodium carboxymethyl cellulose or polyvinyl alcohol; the glidant is one or more of colloidal silica, talc or micronized silica gel; the disintegrant is one or more of low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch or cross-linked Povidone; the lubricant is one or more of magnesium stearate, calcium stearate or sodium stearyl fumarate; a mass ratio of the compound of Formula I to the filler is 1:1.0-2.5, a mass ratio of the compound of Formula I to the binder is 1:0.01-0.05, a mass ratio of the compound of Formula I to the glidant is 1:0.01-0.03, a mass ratio of the compound of Formula I to the disintegrant is 1:0.10-0.30, a mass ratio of the compound of Formula I to the lubricant is 1:0.01-0.10; and the pharmaceutical composition has a moisture content not exceeding 5.0%; preferably, the pharmaceutical composition has a moisture content of 1.0% to 5.0%, preferably 3.0% to 5.0%;



I.

3. A pharmaceutical composition, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and an auxiliary material; the auxiliary material comprises one or more of a filler, a binder, a glidant, a disintegrant and a lubricant; the filler is one or more of lactose, anhydrous lactose, microcrystalline cellulose, mannitol or starch; the binder is one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, Povidone, hydroxyethyl cellulose, sodium carboxymethyl cellulose or polyvinyl alcohol; the glidant is one or more of colloidal silica, talc or micronized silica gel; the disintegrant is one or more of low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch or cross-linked Povidone; the lubricant is one or more of magnesium stearate, calcium stearate or sodium stearyl fumarate; the pharmaceutical composition exhibits a dissolution rate of 70.0% or more at 60 min in a phosphate buffer solution with a pH of 6.8 as a dissolution medium; preferably, the pharmaceutical composition exhibits a dissolution rate of 43.0% or more at 15 min in a phosphate buffer solution with a pH of 6.8 as a dissolution medium; more preferably, the pharmaceutical composition exhibits a dissolution rate of 60.0% or more at 30 min in a phosphate buffer solution with a pH of 6.8 as a dissolution medium;



I.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the filler is a mixture of lactose and microcrystalline cellulose, the binder is hydroxypropyl methylcellulose, the glidant is colloidal silica, the disintegrant is cross-linked sodium carboxymethyl cellulose, and the lubricant is magnesium stearate.

5. The pharmaceutical composition according to claim 3, wherein a mass ratio of the compound of Formula I to the filler is 1:1.0-2.5, a mass ratio of the compound of Formula I to the binder is 1:0.01-0.05, a mass ratio of the compound of Formula I to the glidant is 1:0.01-0.03, a mass ratio of the compound of Formula I to the disintegrant is 1:0.10-0.30, and a mass ratio of the compound of Formula I to the lubricant is 1:0.01-0.10.

6. The pharmaceutical composition according to any one of claims 1 to 3, wherein the mass ratio of

the compound of Formula I to the filler is 1:1.5-2.0, the mass ratio of the compound of Formula I to the binder is 1:0.02-0.04, the mass ratio of the compound of Formula I to the glidant is 1:0.012-0.020, the mass ratio of the compound of Formula I to the disintegrant is 1:0.15-0.25, the mass ratio of the compound of Formula I to the lubricant is 1:0.02-0.06; preferably, the mass ratio of the compound of Formula I to the lubricant is 1:0.02-0.05; preferably, the mass ratio of the compound of Formula I to the filler is 1:1.75, the mass ratio of the compound of Formula I to the binder is 1:0.03, the mass ratio of the compound of Formula I to the glidant is 1:0.015, the mass ratio of the compound of Formula I to the disintegrant is 1:0.18 or 1:0.24, and the mass ratio of the compound of Formula I to the lubricant is 1:0.03 or 1:0.06.

7. The pharmaceutical composition according to any one of claims 1 to 3, wherein the disintegrant is added both intra-granularly and extra-granularly during a preparation, and the lubricant is added both intra-granularly and extra-granularly during a preparation.

8. The pharmaceutical composition according to claim 7, wherein when the disintegrant is added both intra-granularly and extra-granularly during the preparation, a mass ratio of the intragranular disintegrant to the extragranular disintegrant is 1:0.5-3; preferably, the mass ratio of the intragranular disintegrant to the extragranular disintegrant is 1:0.8-2; more preferably, the mass ratio of the intragranular disintegrant to the extragranular disintegrant is 1:1;

or, when the lubricant is added both intra-granularly and extra-granularly during the preparation, a mass ratio of the intragranular lubricant to the extragranular lubricant is 1:0.5-3; preferably, the mass ratio of the intragranular lubricant to the extragranular lubricant is 1:0.8-2; more preferably, the mass ratio of the intragranular lubricant to the extragranular lubricant is 1:1.

9. The pharmaceutical composition according to claim 4, wherein a mass ratio of lactose to microcrystalline cellulose is 1:0.5-5; preferably, the mass ratio of lactose to microcrystalline cellulose is 1:0.6-3; more preferably, the mass ratio of lactose to microcrystalline cellulose is 1:1-3; most preferably, the mass ratio of lactose to microcrystalline cellulose is 1:0.69, 1:0.98 or 1:2.

10. The pharmaceutical composition according to any one of claims 1 to 3, wherein the compound of Formula I has a particle size of D10 ≤ 8 μm, D50 ≤ 25 μm, D90 ≤ 160 μm; preferably, the compound of Formula I has a particle size of D10 ≤ 5 μm, D50 ≤ 20 μm, D90 ≤ 150 μm; more preferably, the compound of Formula I has a particle size of D10 ≤ 3 μm, D50 ≤ 15 μm, D90 ≤ 140 μm.

11. The pharmaceutical composition according to any one of claims 1 to 3, wherein the compound of Formula I is in amorphous form.

12. A pharmaceutical composition, comprising at least one of the following components:

name	amount, mg/tablet
	200.0

compound of Formula I	
lactose	116.4
microcrystalline cellulose	232.6
hydroxypropyl methylcellulose	6.0
colloidal silica	3.0
cross-linked sodium carboxymethyl cellulose - intragranular	18.0
magnesium stearate - intragranular	3.00
cross-linked sodium carboxymethyl cellulose - extragranular	18.0
magnesium stearate - extragranular	3.0

; the compound of Formula I has a particle size of D10 ≤ 3 μm, D50 ≤ 15 μm, D90 ≤ 140 μm; and the compound of Formula I is in amorphous form;

name	amount, mg/tablet
 compound of Formula I	200.0
lactose	176.8
microcrystalline cellulose	173.2
hydroxypropyl methylcellulose	6.0
colloidal silica	3.0
cross-linked sodium carboxymethyl cellulose - intragranular	18.0
magnesium stearate - intragranular	3.0
cross-linked sodium carboxymethyl cellulose - extragranular	18.0
magnesium stearate - extragranular	3.0

; the compound of Formula I has a particle size of D10 ≤ 3 μm, D50 ≤ 15 μm, D90 ≤ 140 μm; and the compound of Formula I is in amorphous form;

name	amount, mg/tablet
 compound of Formula I	200.0

lactose	206.4
microcrystalline cellulose	142.6
hydroxypropyl methylcellulose	6.0
colloidal silica	3.0
cross-linked sodium carboxymethyl cellulose - intragranular	24.0
magnesium stearate - intragranular	6.0
cross-linked sodium carboxymethyl cellulose - extragranular	24.0
magnesium stearate - extragranular	6.0

; the compound of Formula I has a particle size of D10 ≤ 3 μm, D50 ≤ 15 μm, D90 ≤ 140 μm, and the compound of Formula I is in amorphous form;

name	mass, parts
 compound of Formula I	1
lactose	0.582
microcrystalline cellulose	1.163
hydroxypropyl methylcellulose	0.03
colloidal silica	0.015
cross-linked sodium carboxymethyl cellulose - intragranular	0.09
magnesium stearate - intragranular	0.015
cross-linked sodium carboxymethyl cellulose - extragranular	0.09
magnesium stearate - extragranular	0.015

; the compound of Formula I has a particle size of D10 ≤ 3 μm, D50 ≤ 15 μm, D90 ≤ 140 μm; the compound of Formula I is in amorphous form; and the pharmaceutical composition has a moisture content of 3.0% to 5.0%;

name	mass, parts
 compound of Formula I	1

lactose	0.884
microcrystalline cellulose	0.866
hydroxypropyl methylcellulose	0.03
colloidal silica	0.015
cross-linked sodium carboxymethyl cellulose - intragranular	0.09
magnesium stearate - intragranular	0.015
cross-linked sodium carboxymethyl cellulose - extragranular	0.09
magnesium stearate - extragranular	0.015

; the compound of Formula I has a particle size of D10 ≤ 3 μm, D50 ≤ 15 μm, D90 ≤ 140 μm; the compound of Formula I is in amorphous form; and the pharmaceutical composition has a moisture content of 3.0% to 5.0%;

name	mass, parts
 compound of Formula I	1
lactose	1.032
microcrystalline cellulose	0.713
hydroxypropyl methylcellulose	0.03
colloidal silica	0.015
cross-linked sodium carboxymethyl cellulose - intragranular	0.12
magnesium stearate - intragranular	0.03
cross-linked sodium carboxymethyl cellulose - extragranular	0.12
magnesium stearate - extragranular	0.03

; the compound of Formula I has a particle size of D10 ≤ 3 μm, D50 ≤ 15 μm, D90 ≤ 140 μm; the compound of Formula I is in amorphous form; and the pharmaceutical composition has a moisture content of 3.0% to 5.0%;

name	mass, parts
	1

compound of Formula I	
lactose	0.582
microcrystalline cellulose	1.163
hydroxypropyl methylcellulose	0.03
colloidal silica	0.015
cross-linked sodium carboxymethyl cellulose - intragranular	0.09
magnesium stearate - intragranular	0.015
cross-linked sodium carboxymethyl cellulose - extragranular	0.09
magnesium stearate - extragranular	0.015

; the compound of Formula I has a particle size of D10 ≤ 3 μm, D50 ≤ 15 μm, D90 ≤ 140 μm; the compound of Formula I is in amorphous form; and the pharmaceutical composition exhibits a dissolution rate of 70.0% or more at 60 min in a phosphate buffer solution with a pH of 6.8 as a dissolution medium;

name	mass, parts
 compound of Formula I	1
lactose	0.884
microcrystalline cellulose	0.866
hydroxypropyl methylcellulose	0.03
colloidal silica	0.015
cross-linked sodium carboxymethyl cellulose - intragranular	0.09
magnesium stearate - intragranular	0.015
cross-linked sodium carboxymethyl cellulose - extragranular	0.09
magnesium stearate - extragranular	0.015

; the compound of Formula I has a particle size of D10 ≤ 3 μm, D50 ≤ 15 μm, D90 ≤ 140 μm; the compound of Formula I is in amorphous form; and the pharmaceutical composition exhibits a dissolution rate of 70.0% or more at 60 min in a phosphate buffer solution with a pH of 6.8 as a dissolution medium;

name	mass, parts

 compound of Formula I	1
lactose	1.032
microcrystalline cellulose	0.713
hydroxypropyl methylcellulose	0.03
colloidal silica	0.015
cross-linked sodium carboxymethyl cellulose - intragranular	0.12
magnesium stearate - intragranular	0.03
cross-linked sodium carboxymethyl cellulose - extragranular	0.12
magnesium stearate - extragranular	0.03

; the compound of Formula I has a particle size of D10 ≤ 3 μm, D50 ≤ 15 μm, D90 ≤ 140 μm; the compound of Formula I is in amorphous form; and the pharmaceutical composition exhibits a dissolution rate of 70.0% or more at 60 min in a phosphate buffer solution with a pH of 6.8 as a dissolution medium.

13. A preparation method for the pharmaceutical composition of any one of claims 1 to 12, wherein the preparation method is a non-wet granulation preparation technology.

14. A pharmaceutical tablet, comprising a core and a coating covering the core, the core is composed of the pharmaceutical composition of any one of claims 1 to 12; preferably, the coating is a gastric-soluble film coating; preferably, a mass of the coating is 0.5%-10% of a mass of the core, preferably 1%-6%, more preferably 3%.

15. The pharmaceutical composition of any one of claims 1 to 12 or the pharmaceutical tablet of claim 14 for preventing, alleviating or treating an infection or a disease caused by SARS-CoV-2.